Mariusz Niemczyk1, Leszek Paczek. 1. Department of Immunology, Transplant Medicine, and Internal Diseases, Medical University of Warsaw, Poland. mariuszniemczyk@wp.pl
Abstract
BACKGROUND: Equoral(®) is a generic formulation of Cyclosporine A (CsA), which is significantly cheaper than the original medicine. Our center participated in the clinical trial designed to evaluate the efficacy and safety of Equoral(®) in kidney transplant recipients in the first 9 months after a transplant procedure. The aim of our paper is to present the 5-year follow-up of patients who participated in the study and were monitored in our center. MATERIAL/ METHODS: We performed intention-to-treat retrospective analysis of 20 de novo kidney transplant recipients who received Equoral®-based immunosuppressive regimen and were monitored in our department for 5 years after transplantation. RESULTS: The 5-year patient and graft survival was 90%, and the frequency of acute rejection was 15%. In 80% of patients, the initial immunosuppressive regimen had to be changed. CONCLUSIONS: In our group of kidney transplant recipients, immunosuppression based on generic formulation of CsA had excellent 5-year patient and graft survival and effectively prevented acute rejection episodes. However, most patients needed modification of the initially administered immunosuppressive regimen.
BACKGROUND: Equoral(®) is a generic formulation of Cyclosporine A (CsA), which is significantly cheaper than the original medicine. Our center participated in the clinical trial designed to evaluate the efficacy and safety of Equoral(®) in kidney transplant recipients in the first 9 months after a transplant procedure. The aim of our paper is to present the 5-year follow-up of patients who participated in the study and were monitored in our center. MATERIAL/ METHODS: We performed intention-to-treat retrospective analysis of 20 de novo kidney transplant recipients who received Equoral®-based immunosuppressive regimen and were monitored in our department for 5 years after transplantation. RESULTS: The 5-year patient and graft survival was 90%, and the frequency of acute rejection was 15%. In 80% of patients, the initial immunosuppressive regimen had to be changed. CONCLUSIONS: In our group of kidney transplant recipients, immunosuppression based on generic formulation of CsA had excellent 5-year patient and graft survival and effectively prevented acute rejection episodes. However, most patients needed modification of the initially administered immunosuppressive regimen.
Authors: Natalia Riva; Paulo Caceres Guido; Juan Ibañez; Nieves Licciardone; Marcela Rousseau; Gabriel Mato; Marta Monteverde; Paula Schaiquevich Journal: Int J Clin Pharm Date: 2014-05-27
Authors: Maximilian Kraeuter; Matthias Helmschrott; Christian Erbel; Christian A Gleissner; Lutz Frankenstein; Bastian Schmack; Arjang Ruhparwar; Philipp Ehlermann; Hugo A Katus; Andreas O Doesch Journal: Drug Des Devel Ther Date: 2013-11-28 Impact factor: 4.162